Efficacy and Tolerability of Fixed Dose Combination of Indapamide S.R. (1.5 mg) + Amlodipine (5 mg) in patients suffering from stage II/III hypertension

Serdia Pharmaceuticals India Pvt Ltd0 个研究点目标入组 240 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Newly diagnosed untreated hypertensive patients having a baseline blood pressure > 160/100 mmHg) OR
•2.Uncontrolled patients of hypertension with a baseline blood pressure > 140/90 mmHg on monotherapy with a Calcium Channel Blocker (CCB)
•3.Patients of either sex
•4.With confirmed diagnosis of Stage II/ III (moderate to severe) hypertension, as per JNC 7 guidelines

•1)Uncontrolled diabetes
•2)H/o myocardial infarction within the previous 3 months
•3)H/o cerebrovascular event within previous 3 months
•4)Uncontrolled arrhythmias
•5)H/o Heart failure
•6)Patients with severe impaired renal function serum creatinine levels > 5.3 mg/dl and / or serious liver disorders
•7)Patients unwilling to give informed consent.
•8)Patients with history of hypersensitivity to Indapamide or Amlodipine
•9)Any contraindication to Thiazide type diuretic and/or CCB
•10)Pregnancy or lactation
•11)Patients with any other condition or disease, which in opinion of the investigator could preclude evaluation of response to study medication or hamper the safety of the trial participant.
•12)Patients previously enrolled in similar trial in the last 6 months

发起方